242 related articles for article (PubMed ID: 26763256)
1. Propensity Score Analysis Comparing Clinical Outcomes of Drug-Eluting vs Bare Nitinol Stents in Femoropopliteal Lesions.
Soga Y; Takahara M; Iida O; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Ando K
J Endovasc Ther; 2016 Feb; 23(1):33-9. PubMed ID: 26763256
[TBL] [Abstract][Full Text] [Related]
2. Comparative Outcomes of Supera Interwoven Nitinol vs Bare Nitinol Stents for the Treatment of Femoropopliteal Disease: Insights From the XLPAD Registry.
Armstrong EJ; Jeon-Slaughter H; Kahlon RS; Niazi KA; Shammas NW; Banerjee S
J Endovasc Ther; 2020 Feb; 27(1):60-65. PubMed ID: 31686573
[No Abstract] [Full Text] [Related]
3. Drug-Eluting Versus Bare-Metal Stent Implantation With or Without Cilostazol in the Treatment of the Superficial Femoral Artery.
Miura T; Miyashita Y; Soga Y; Hozawa K; Doijiri T; Ikeda U; Kuwahara K;
Circ Cardiovasc Interv; 2018 Aug; 11(8):e006564. PubMed ID: 30354784
[TBL] [Abstract][Full Text] [Related]
4. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
Zen K; Takahara M; Iida O; Soga Y; Kawasaki D; Nanto S; Yokoi H; Matoba S;
J Vasc Surg; 2017 Mar; 65(3):720-725. PubMed ID: 28073668
[TBL] [Abstract][Full Text] [Related]
5. Impact of Drug-Eluting Stent Implantation for Femoropopliteal In-Stent Occlusion.
Tomoi Y; Soga Y; Iida O; Shiraki T; Kobayashi Y; Hiramori S; Ando K
J Endovasc Ther; 2016 Jun; 23(3):461-7. PubMed ID: 27004496
[TBL] [Abstract][Full Text] [Related]
6. Retrospective Multicenter Comparison Between Viabahn Covered Stent-Grafts and Supera Interwoven Nitinol Stents for Endovascular Treatment in Severely Calcified Femoropopliteal Artery Disease: The ARMADILLO Study (Adjusted Retrospective coMparison of scAffolDs In caLcified LesiOns).
Horie K; Takahara M; Nakama T; Tanaka A; Tobita K; Hayakawa N; Mori S; Iwata Y; Suzuki K
J Endovasc Ther; 2024 Jun; 31(3):400-409. PubMed ID: 36146948
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of polymer-free, paclitaxel-coated stents vs stent grafts in peripheral arterial disease patients with femoropopliteal artery lesions.
Tsujimura T; Takahara M; Iida O; Soga Y; Katsuki T; Fujihara M; Kawasaki D; Kozuki A; Mano T
J Vasc Surg; 2021 Jun; 73(6):1998-2008.e1. PubMed ID: 33347998
[TBL] [Abstract][Full Text] [Related]
8. Drug-Eluting Stent vs Percutaneous Transluminal Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis: Results From a Retrospective 1-Year Multicenter Study.
Murata N; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Yokoi H; Tosaka A; Tanaka N; Iida O
J Endovasc Ther; 2016 Aug; 23(4):642-7. PubMed ID: 27099284
[TBL] [Abstract][Full Text] [Related]
9. Retrospective Multicenter Comparison of S.M.A.R.T. CONTROL and MISAGO Stents in Treatment of Femoropopliteal Lesions.
Suzuki K; Takahara M; Shintani Y; Tanaka A; Soga Y; Yamaoka T; Tosaka A; Sasaki S; Kawasaki D; Tsuchiya T; Kozuki A; Iida O
J Vasc Interv Radiol; 2016 Nov; 27(11):1642-1649. PubMed ID: 27567999
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of intravascular ultrasound in femoropopliteal stenting for peripheral artery disease with TASC II class A to C lesions.
Iida O; Takahara M; Soga Y; Suzuki K; Hirano K; Kawasaki D; Shintani Y; Suematsu N; Yamaoka T; Nanto S; Uematsu M
J Endovasc Ther; 2014 Aug; 21(4):485-92. PubMed ID: 25101575
[TBL] [Abstract][Full Text] [Related]
11. The Characteristics of In-Stent Restenosis After Drug-Eluting Stent Implantation in Femoropopliteal Lesions and 1-Year Prognosis After Repeat Endovascular Therapy for These Lesions.
Iida O; Takahara M; Soga Y; Hirano K; Yamauchi Y; Zen K; Kawasaki D; Nanto S; Yokoi H; Uematsu M;
JACC Cardiovasc Interv; 2016 Apr; 9(8):828-834. PubMed ID: 27101908
[TBL] [Abstract][Full Text] [Related]
12. Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement.
Ichihashi S; Shibata T; Fujimura N; Nagatomi S; Yamamoto H; Kyuragi R; Adachi A; Iwakoshi S; Bolstad F; Saeki K; Obayashi K; Kichikawa K
J Endovasc Ther; 2019 Oct; 26(5):613-620. PubMed ID: 31257994
[No Abstract] [Full Text] [Related]
13. Combination therapy of heparin-bonded covered stent and bare-nitinol stent assessed by intravascular ultrasound.
Katsuki T; Tomoi Y; Yamaji K; Soga Y; Imada K; Ito N; Hiramori S; Ando K
Heart Vessels; 2020 Nov; 35(11):1502-1509. PubMed ID: 32462463
[TBL] [Abstract][Full Text] [Related]
14. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
Tran K; Ullery BW; Kret MR; Lee JT
Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
[TBL] [Abstract][Full Text] [Related]
15. Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease.
Müller-Hülsbeck S; Keirse K; Zeller T; Schroë H; Diaz-Cartelle J
J Endovasc Ther; 2016 Oct; 23(5):701-7. PubMed ID: 27193308
[TBL] [Abstract][Full Text] [Related]
16. Nitinol stent implantation for femoropopliteal disease in patients on hemodialysis: results of the 3-year retrospective multicenter APOLLON study.
Fujihara M; Higashimori A; Kato Y; Taniguchi H; Iwasaki Y; Amano T; Sumiyoshi A; Nishiya D; Yokoi Y
Heart Vessels; 2016 Sep; 31(9):1476-83. PubMed ID: 26337619
[TBL] [Abstract][Full Text] [Related]
17. Analysis of endovascular therapy for femoropopliteal disease with the Supera stent.
Montero-Baker M; Ziomek GJ; Leon L; Gonzales A; Dieter RS; Gadd CL; Pacanowski JP
J Vasc Surg; 2016 Oct; 64(4):1002-8. PubMed ID: 27444365
[TBL] [Abstract][Full Text] [Related]
18. Midterm Patency After Femoropopliteal Interventions: A Comparison of Standard and Interwoven Nitinol Stents and Drug-Coated Balloons in a Single-Center, Propensity Score-Matched Analysis.
Steiner S; Schmidt A; Bausback Y; Piorkowski M; Werner M; Yahiaoui-Doktor M; Banning-Eichenseer U; Scheinert D
J Endovasc Ther; 2016 Apr; 23(2):347-55. PubMed ID: 26848131
[TBL] [Abstract][Full Text] [Related]
19. Intravascular ultrasound measurements after drug-eluting stent placement in femoropopliteal lesions: determining predictors of restenosis.
Mori S; Hirano K; Nakano M; Muramatsu T; Tsukahara R; Ito Y; Ishimori H
J Endovasc Ther; 2015 Jun; 22(3):341-9. PubMed ID: 25862363
[TBL] [Abstract][Full Text] [Related]
20. Covered vs Uncovered Stents for Aortoiliac and Femoropopliteal Arterial Disease: A Systematic Review and Meta-analysis.
Hajibandeh S; Hajibandeh S; Antoniou SA; Torella F; Antoniou GA
J Endovasc Ther; 2016 Jun; 23(3):442-52. PubMed ID: 27099281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
